THE INTERSECTION OF BRAIN SCIENCE & HUMAN POTENTIALPartner with us
neurofeedback.com
The newsletter
← Research & Evidence
Positive with limitationsNonrandomized controlled study

The effects of swLORETA Z-score neurofeedback for patients comorbid with major depressive disorder and anxiety symptoms.

Patients receiving neurofeedback had lower depression and anxiety scores after treatment than the comparison group. Because allocation was not randomized, other differences could explain some of the results.

Wu YC, Yu HE, Yen CF, Yeh YC, Jian CR, Lin CW, Lin IM.
Journal of affective disorders · Publication date: 2024-01-08
Added to site: 2026-09-09
DOI: 10.1016/j.jad.2024.01.020

Publication date recorded by Europe PMC; online and issue dates may differ.

Modalities
Neurofeedback, swLORETA, Z-score
Clinical focus
Depression, Anxiety
Population
Patients with major depression and anxiety symptoms
Sample
48 patients
Intervention / method
Ten one-hour swLORETA Z-score sessions, twice weekly
Comparator
Treatment as usual

Clinician summary

The study reported favorable post-treatment BDI-II and BAI comparisons, with EEG changes. The authors explicitly identify the lack of randomization as a limitation.

How to interpret the findings

Nonrandomized allocation and short pre/post observation limit causal inference and conclusions about durability.

Equipment and disclosures

swLORETA Z-score training is identified; hardware is not verified from the abstract.

Funding and competing-interest disclosures were not verified from the reviewed abstract.

Related evidence

Compare findings from the same clinical area, including mixed results.

Abstract checked · Checked 2026-09-09

Summary prepared with AI assistance. Source verification does not imply an independent replication or a clinician's endorsement. Read our review method.